SECONDARY MYELODYSPLASTIC SYNDROME
Clinical trials for SECONDARY MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new SECONDARY MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for SECONDARY MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New chemo combo aims to keep leukemia from returning after transplant
Disease control OngoingThis study tests whether giving two chemotherapy drugs, clofarabine and melphalan, before a donor stem cell transplant can help prevent leukemia or myelodysplasia from coming back. The trial includes 72 adults whose cancer is in remission or who have high-risk myelodysplastic syn…
Matched conditions: SECONDARY MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 02:53 UTC
-
New combo therapy shows promise for Treatment-Linked blood cancer
Disease control OngoingThis study tests whether combining two drugs, venetoclax and azacitidine, can help people with a type of blood cancer called therapy-related myelodysplastic syndrome (t-MDS), which develops after prior cancer treatment. About 33 adults with intermediate to very high risk t-MDS wi…
Matched conditions: SECONDARY MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Experimental combo aims to outsmart resistant blood cancers
Disease control OngoingThis early-phase study tests a combination of two drugs—ipilimumab (an immunotherapy that helps the immune system attack cancer) and decitabine (a chemotherapy drug)—in adults with myelodysplastic syndrome or acute myeloid leukemia that has returned or not responded to prior trea…
Matched conditions: SECONDARY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC